GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B7949 LiraglutideTarget: GLP-1 receptor -
B8208 Naloxone (hydrochloride)Summary: An opioid receptor antagonist that relieves respiratory depression caused by opioid overdose -
B8303 EpinastineSummary: An antihistamine and mast cell stabilizer for the treatment of itching associated with allergic conjunctivitis -
B8316 HarmineSummary: Harmine -
B8385 BAY-293Summary: Potent SOS1 inhibitor, disrupts KRAS-SOS1 interaction -
B8718 DolasetronSummary: A 5-HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting -
B8399 AMG 510Summary: An effective, orally bioavailable, selective covalent KRAS G12C inhibitor -
C6376 Adenosine 5'-monophosphate monohydrateSummary: An adenosine A1 receptor agonist for inhibiting HSV replication -
C6389 Atropine sulfate -
C6391 Betahistine mesylateSummary: An orally active H1 receptor agonist and H3 receptor antagonist

